Stanford Advanced Therapeutics for Heart Failure Research Laboratory

Dr. Joseph Woo's Laboratory

The Stanford Advanced Therapeutics for Heart Failure Research Laboratory focuses on developing and translating potential therapies for the treatment and prevention of heart failure via:

  • Angiogenic tissue engineering
  • Myocardial regeneration with specific growth factors and stem cells
  • Circumventing ischemia through manipulation of endosymbiotic relationships

Pediatric Cardiac Surgery Lab

The Pediatric Cardiac Surgery Lab research program is focused on three aspects of surgery for congenital cardiac disease:

  • Development of surgical and technological approaches for cardiac surgery in the fetus.
  • Reduction of morbidity associated with pediatric cardiac surgery patients.
  • Bioengineering of heart valves and vascular tissues for pediatric applications.

Thoracic Surgery Lab

There are two active basic/translational research laboratories within the Division of Thoracic Surgery. These are:

  • Thoracic Oncology Research Laboratory which has interests in the biology of non-small cell lung cancer and mesothelioma (an aggressive malignancy of the pleura, or chest lining)
  • Respiratory Muscle Research Laboratory, which is directed by Dr. Joseph Shrager in collaboration with Dr. Huibin Tang, PhD,  this laboratory is focused upon the responses of the respiratory muscles, in particular the diaphragm, to various disease states and interventions

Stanford Thoracic Surgery Clinical Research Program

Drs. Leah Backhus and Mark Berry's Laboratory

The Stanford Thoracic Surgery Clinical Outcomes and Health Services Research Center uses a variety of research methodologies geared towards assessing the quality and effectiveness of thoracic surgical interventions for individual patients as well as population-based research. We have a multidisciplinary team which includes senior statistical support as well as faculty collaborations from the School of Engineering, Biodesign, Pulmonary Medicine, Plastic Surgery, Surgical Oncology, Radiation Oncology, and Medical Oncology.  Our goal is to integrate health services research into the advancement of thoracic surgical care emphasizing clinical outcomes, quality of care, and cost integral in defining best practices in academic thoracic surgery.

Stanford Thoracic Aortic Research Laboratory

Dr. Michael Fischbein's Laboratory

The Stanford Thoracic Aortic Research Laboratory focuses on advancing the understanding of the molecular and cellular mechanisms of aortic aneurysm formation, with particular interest in patients with Marfan Syndrome. Investigative studies include:

  • Genomic and transcriptomic analyses of pathogenesis of aortic aneurysms arising due to Marfan Syndrome
  • Development of in vitro disease models of Marfan Syndrome using primary culture cells and inducible pluripotent stem cell (iPSC) technologies
  • Use of an in vivo murine model of Marfan Syndrome to study aortic aneurysm formation via biological assays including gene expression quantification, protein modification analyses, and immunohistochemistry.

Cardiac Surgical Arrhythmia Research Laboratory

Dr. Anson Lee's Laboratory

The Cardiac Surgical Arrhythmia Research Laboratory is working to advance the understanding of the mechanisms of atrial fibrillation and to apply that understanding to develop potential therapies to treat atrial fibrillation and other forms of tachycardia.

Stanford Cardiothoracic Therapeutics and Surgery Laboratory

Dr. William Hiesinger's Laboratory

The Stanford Cardiothoracic Therapeutics and Surgery Laboratory uses protein therapeutics, heart computer modeling and simulations, molecular biology, 3-D printed blood vessels, and cardiovascular biodevices to tackle a variety of challenges including examining the cellular and molecular mechanisms that transform stable coronary-artery disease to unstable coronary syndromes and clinical inventions to aid or cure patients.

Stanford Cardiovascular Tissue Engineering Laboratory

Dr. Ngan Huang's Laboratory

The Stanford Cardiovascular Tissue Engineering Laboratory employs extracellular matrix proteins and biomaterials to:

  • Elucidate the role of biochemical and biomechanical cues on stem cell differentiation and mechanobiology
  • Engineer three-dimensional engineered cardiovascular tissues for preclinical testing
  • Develop microscale devices for studying cell function in unprecedented ways

Clinical and Translational Research Program

Betty Irene Moore Children's Heart Center

The Clinical and Translational Research Program (CTRP), which launched in fall 2014, is led by Doff McElhinney, MD, and promises to promote a collaborative framework to support research discoveries by the faculty, clinicians, and other members of the Betty Irene Moore Children's Heart Center. 

This novel program is designed to meet the evolving needs of the patient community and to act as the platform for the Heart Center to assume a leading national and international role in advancing the field.

Rare Cardiac Disease Research Laboratory

Dr. Ioannis Karakikes's Laboratory

The Rare Cardiac Disease Research Laboratory aims to uncover fundamental new insights into the molecular mechanisms and functional consequences of pathogenic mutations associated with familial cardiovascular diseases.

The overarching goal of our studies is to improve our understanding of the pathogenesis of familial cardiomyopathies, such as Hypertrophic Cardiomyopathy (HCM) and Dilated Cardiomyopathy (DCM). We utilize isogenic patient specific induced pluripotent stem cells (iPSCs) as a platform for disease modeling to again insights on how rare mutations affect the cardiomyocyte biology and cardiac performance. By establishing a deep understanding of the biology of the disease, our studies represent a first definitive step in elucidating the genotype-phenotype associations in HCM and DCM toward applying a precision medicine approach to the treatment of cardiomyopathies.

Stanford Translational Heart Failure Research Laboratory

Dr. Yasuhiro Shudo's Laboratory

The Shudo laboratory strives to develop novel tissue engineering strategies, such as bioengineering, biomechanical, and biostatistical approaches to treat end-stage heart failure (ESHF). We hope this research can be successfully translated to the clinical arena to impact progression to heart failure following myocardial infarction positively.

Moreover, our clinical focus is on the surgical treatment for ESHF, with a particular emphasis on the outcome of the orthotopic heart transplant, heart-lung transplant, and mechanical circulatory support (MCS), including extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD).

Cardiothoracic Advanced Surgical Materials Laboratory

Dr. John W. MacArthur's Laboratory

The Cardiothoracic Advanced Surgical Materials Laboratory is a cardiothoracic research lab that is interested in investigating and developing strategies to treat heart failure, valvular heart disease, cardiac revascularization and lung injuries.

Cardiothoracic Surgery's Human Biorepository Tissue Bank

The Stanford Department of Cardiothoracic Surgery's Human Biorepository Tissue Bank directs and maintains an extensive collection of 5,000 human cardiothoracic tissue samples obtained from consented patients. The purpose of our tissue bank is to create a comprehensive biorepository resource and have it available for approved studies to advance cardiovascular and pulmonary disease research and discoveries. We have collaborated with more than 30 collaborators and Stanford labs. Our goal is to promote research by providing cardiothoracic tissue samples to researchers and scientists across Stanford Medicine.

Faculty Publications

The Department of Cardiothoracic Surgery is dedicated to the principles of vision, perseverance, and rigorous scientific investigation in its commitment to conducting well-conceived, cutting-edge research. The department generates dozens of peer-reviewed journal publications annually in its efforts to maintain its respected status among cardiothoracic research groups worldwide.

Clinical Trials

Stanford clinician scientists are engaged in a wide variety of clinical trials investigating new approaches to preventing and treating conditions and diseases. The variety of therapies being studied range from new pharmaceutical drugs and medical devices to behavioral and biotechnology therapies. These trials are done in close collaboration with scientists and physicians from many areas of expertise across Stanford University. To insure the highest ethical standards are maintained the Institutional Review Board (IRB) is responsible for oversight of all studies.

Stanford Cardiovascular Institute

Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Institute is home to Stanford's myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists and other researchers in heart and vessel disease and prevention.